Navigation Links
Arpida Reports Interim Results For Six Months to 30 June 2009
Date:8/19/2009

REINACH, Switzerland, August 19 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the six months ending 30 June 2009.

    Key events 2009 to date

    - Regulatory setback for intravenous iclaprim in cSSSI in U.S.A.
    - Strategic options under review
    - Company restructuring completed

Cash and financial investments of CHF 22.7 million at 30 June 2009

CFO Harry Welten, MBA, commented: "Our cost-saving measures have been implemented, resulting in a substantial reduction of the cash burn. We expect to have cash and financial investments of around CHF 14 million at the end of 2009."

Dr Jurgen Raths, President and CEO, commented: "Arpida is going through challenging times. We've completed a painful restructuring process in anticipation of a possible strategic deal. We remain fully committed to finding a strategic partner and securing the maximum value for our shareholders. Discussions are ongoing, as soon as these advance, we will provide an update."

The full 10 page text is available under: http://www.arpida.com

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:

    Dr Jurgen Raths, President and CEO
    Tel: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel: +41-61-417-96-65

    Paul Verbraeken, Head of Corporate Communications
    Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. Arpida to Discuss Strategy With Shareholders
3. Arpida Announces Full Year 2008 Financial Results
4. Arpida to Restructure and Focus on Key Projects
5. Arpidas iclaprim MAA Accepted for Review by EMEA
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
8. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
9. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
10. Arpida Announces Conference Call on 17 April
11. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... Nov. 30, 2016  The Allen Institute for ... the first publicly available collection of gene edited, ... target key cellular structures with unprecedented clarity. Distributed ... powerful tools are a crucial first step toward ... understand what makes human cells healthy and what ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
Breaking Biology Technology:
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... offering. The report forecasts the ... at a CAGR of 12.28% during the period 2016-2020. ... analysis with inputs from industry experts. The report covers the market ... also includes a discussion of the key vendors operating in this ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):